2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.063 Vivian Altiery De Jesus NACLC Abstract

PP01.063 Vivian Altiery De Jesus NACLC Abstract

Pdf Summary

Plasma genotyping is a technique used in the management of advanced non-small cell lung cancer (NSCLC) that offers advantages over tissue genotyping. It is accessible, provides rapid results, and captures tumor genetic heterogeneity. However, there is no consensus on its role in NSCLC management, and inconsistent practices in genomic testing could lead to disparities in patient outcomes. This study aimed to compare the characteristics of patients who underwent plasma genotyping alone versus those who had plasma and tissue genotyping.<br /><br />The study analyzed data from 718 NSCLC patients who underwent plasma genotyping between 2015 and 2022 at three hospitals. Clinical data, including tissue genotyping, was obtained from the electronic health records. The demographic data showed that most patients had both plasma and tissue genotyping. A small fraction of patients were Hispanic (1.8%) or American Indian (1%).<br /><br />When comparing the two groups, no statistically significant differences were found in terms of race, smoking status, age, or receiving a matched therapy. The proportion of patients who received a matched therapy did not differ significantly across different races. These findings suggest that plasma genotyping may provide similar information to the current standard tissue genotyping.<br /><br />The study concludes that there is no significant difference between plasma genotyping alone and plasma and tissue genotyping in terms of race, smoking status, age, and receiving a matched therapy. This indicates that plasma genotyping could potentially serve as a reliable alternative to tissue genotyping. Further research is needed, particularly in underrepresented groups, and in comparison to patients who did not undergo any testing.

Keywords

plasma genotyping

non-small cell lung cancer

NSCLC management

tissue genotyping

genomic testing

patient outcomes

data analysis

matched therapy

genetic heterogeneity

underrepresented groups